Equities
Health CareHealth Care Equipment & Services
  • Price (USD)116.04
  • Today's Change1.99 / 1.74%
  • Shares traded854.33k
  • 1 Year change12.41%
  • Beta1.3610
Data delayed at least 15 minutes, as of Jul 03 2020 00:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

  • Revenue in USD (TTM)7.66bn
  • Net income in USD771.00m
  • Incorporated1996
  • Employees47.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Mid America Clinical Laboratories LLCAnnounced23 Jun 202023 Jun 2020Announced5.58%--
Memorial Hermann Healthcare System-Laboratories & Service CentersDeal completed27 Jan 202027 Jan 2020Deal completed7.65%--
Blueprint Genetics OyDeal completed22 Jan 202022 Jan 2020Deal completed8.11%--
Data delayed at least 15 minutes, as of Jul 03 2020 00:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NeoGenomics, Inc.419.28m3.45m3.74bn1.70k1,064.077.07108.058.930.03180.03183.984.790.662614.904.59246,637.100.5455-0.07380.6136-0.08346.7745.160.8233-0.11352.883.160.1694--47.7336.2531.5047.8839.64--
1life Healthcare Inc292.00m-79.74m4.83bn1.70k--10.07--16.55-0.6514-0.65142.393.80------171,767.10--------37.88---27.81--4.75--0.0047--29.89---18.32------
LHC Group, Inc.2.09bn98.89m5.60bn15.17k55.983.8540.762.683.173.1766.9145.990.9893--6.74137,806.705.596.266.677.5636.6137.095.654.90--14.420.16350.0014.9323.1850.5734.39-16.35--
Encompass Health Corp4.66bn342.40m6.18bn31.57k17.994.289.441.323.453.4546.9414.530.7956--8.93147,703.507.337.249.138.9996.2896.199.218.91--4.230.647433.987.6614.1723.3211.4916.557.12
Amedisys Inc1.98bn127.33m6.61bn21.30k53.029.7344.293.343.853.8559.8620.981.51--7.8492,956.719.788.5712.7811.6941.3741.166.484.28--19.490.36510.0017.6310.186.2757.73-8.06--
Livongo Health Inc206.96m-45.94m7.12bn671.00--14.13--34.41-0.5023-0.50232.255.150.55063.915.03336,520.30-12.21---13.67--73.85---22.17--10.23--0.00--148.71---65.05------
Chemed Corporation1.99bn231.15m7.42bn16.64k33.4110.8026.503.7213.9913.99120.5943.281.70198.2615.67119,723.5019.6915.6524.5419.6132.1930.6211.608.630.776149.810.189711.968.755.897.0017.234.008.10
Universal Health Services, Inc.11.40bn720.84m7.95bn67.70k11.421.476.470.6978.198.19129.7263.740.9771--7.38168,442.206.297.387.408.67----6.447.510.98926.380.40945.615.636.765.208.3210.1314.87
Davita Inc11.49bn816.13m9.87bn65.00k13.925.075.960.85945.826.3579.8615.990.571479.286.09176,717.005.154.477.675.8031.0129.499.017.131.774.890.71870.00-0.1436-2.3014.45-0.4923.63--
Molina Healthcare, Inc.17.26bn717.00m10.78bn10.00k15.926.5213.450.624511.4311.43275.2627.922.35--11.651,725,900.009.753.3520.958.2317.4315.244.151.35--12.290.52920.00-10.9111.734.2463.76-13.09--
Quest Diagnostics Inc7.66bn771.00m15.52bn47.00k20.492.7514.262.035.665.8156.3042.220.638544.927.47162,914.906.326.907.467.9734.3036.969.909.701.277.340.411234.052.590.770816.138.755.3710.45
Laboratory Corp. of America Holdings11.59bn321.00m16.55bn65.00k52.402.3618.261.433.253.25118.2272.300.676334.435.87178,267.701.884.902.205.6227.5429.712.787.041.076.540.47250.001.9513.96-11.2910.0114.48--
Data as of Jul 03 2020. Currency figures normalised to Quest Diagnostics Inc's reporting currency: US Dollar USD

Institutional shareholders

39.85%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202015.10m11.29%
BlackRock Fund Advisorsas of 31 Mar 20207.64m5.72%
SSgA Funds Management, Inc.as of 31 Mar 20206.82m5.10%
American Century Investment Management, Inc.as of 31 Mar 20205.26m3.94%
Fiduciary Management, Inc.as of 31 Mar 20204.66m3.48%
Davis Selected Advisers LPas of 31 Mar 20203.87m2.89%
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 20203.53m2.64%
JPMorgan Investment Management, Inc.as of 31 Mar 20202.30m1.72%
Geode Capital Management LLCas of 31 Mar 20202.20m1.65%
Dimensional Fund Advisors LPas of 31 Mar 20201.91m1.43%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.